Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remifentanil + remimazolam
- Development stage
- Unknown
- Lead developer
- Paion
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of remifentanil (an ultra-short-acting μ-receptor agonist opioid) and remimazolam (a novel ultra-short-acting benzodiazepine) used for anesthesia and sedation procedures. This combination provides rapid onset and offset of action with synergistic effects, making it suitable for short surgical procedures and interventions requiring quick recovery without residual neuromuscular blockade.
02
Targets
MOR (Mu opioid receptor)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on remifentanil + remimazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remifentanil + remimazolam.